<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1053">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 10, 2022</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04509271</url>
  </required_header>
  <id_info>
    <org_study_id>WT20200808</org_study_id>
    <nct_id>NCT04509271</nct_id>
  </id_info>
  <brief_title>Study on Novel Peripheral Blood Diagnostic Biomarkers for MCI Due to Alzheimer's Disease</brief_title>
  <acronym>Precision1000</acronym>
  <official_title>Shanghai Mental Health Center</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Mental Health Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prevalence of Mild Cognitive Impairment (MCI) is about 15%-17%. 10%-15% of MCI progresses&#xD;
      to Alzheimer's disease (AD) every year. The annual incidence of MCI in the normal elderly is&#xD;
      about 1%. Peripheral Blood biomarkers is the key and difficult points in AD research. Except&#xD;
      expensive brain Î² amyloid plaque imaging, few breakthroughs of early diagnosis technology of&#xD;
      MCI due to AD can be made to facilitate clinical application. Even Tau-181 and Tau-217 were&#xD;
      reported in this year on Lancet neurology and JAMA. We also need to study on the biomarkers&#xD;
      upstream of pathological changes about senile plaque. The purpose of this program is to study&#xD;
      the reliability and validity of plasma miRNAs for early diagnosis of MCI due to AD and other&#xD;
      dementia such as DLB and FTLD. The clinical diagnosis of AD and MCI due to AD are according&#xD;
      to the National Institute of Aging and the Alzheimer's Disease Association (NIA-AA)&#xD;
      diagnostic criteria in 2011. Plaque imaging is used to be golden criteria for the diagnosis&#xD;
      of AD and MCI due to AD.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The diagnostic accuracy of biomarkers for MCI due to AD and other dementia.</measure>
    <time_frame>1 and half years</time_frame>
    <description>MicRNAs battery for diagnostic of MCI due to AD</description>
  </primary_outcome>
  <number_of_groups>7</number_of_groups>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>Normal aged</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>MCI due to AD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild AD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate AD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Severe AD</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Dementia with Lewy body</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Frontotemporal dementia</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MicRNAs battery kits</intervention_name>
    <description>Novel peripheral blood diagnostic biomarker for MCI due to AD.</description>
    <arm_group_label>Dementia with Lewy body</arm_group_label>
    <arm_group_label>Frontotemporal dementia</arm_group_label>
    <arm_group_label>MCI due to AD</arm_group_label>
    <arm_group_label>Mild AD</arm_group_label>
    <arm_group_label>Moderate AD</arm_group_label>
    <arm_group_label>Normal aged</arm_group_label>
    <arm_group_label>Severe AD</arm_group_label>
  </intervention>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Peripheral blood plasma and non-coding RNA&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        NC, AD, DLB, FTD and MCI due to AD&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  2011 NIA-AA criteria of MCI due to AD or AD or - 2017 Diagnosis and management of&#xD;
             dementia with Lewy bodies: Fourth consensus report of the DLB Consortium or - 2001 the&#xD;
             McKhann consensus clinical criteria for FTD (McKhann et al.)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Dementia caused by infection or substance&#xD;
&#xD;
          -  Thyroid disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Tao Wang, M.D., Ph.D.</last_name>
    <phone>+862164387250</phone>
    <email>wtshhwy@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shanghai Mental Health Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tao Wang, Ph.D.</last_name>
      <email>wtshhwy@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 9, 2020</study_first_submitted>
  <study_first_submitted_qc>August 9, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 12, 2020</study_first_posted>
  <last_update_submitted>September 21, 2021</last_update_submitted>
  <last_update_submitted_qc>September 21, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>According to the approval of IRB.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

